Financial

CorWave Announces the Appointment of Fairuz Hasni as Vice President Human Resources

CLICHY, France–(BUSINESS WIRE)–CorWave, a French company that develops and manufactures innovative cardiac assist devices, announces the appointment of Fairuz Hasni as Vice President Human Resources. Fairuz Hasni has over twenty years of experience in industrial companies. She will support CorWave in the development of its HR functions and in its […]

OXFORD PROPERTIES BREAKS GROUND ON 165,000 SQ FT EXPANSION OF IONIS PHARMACEUTICALS CARLSBAD CAMPUS

– Build to suit development will expand Ionis’ campus footprint to over 400,000 square feet; grow Oxford’s San Diego life sciences portfolio to more than 1 million square feet -CARLSBAD, Calif., Dec. 5, 2023 /PRNewswire/ – Oxford Properties Group (“Oxford”), a leading global real estate investor, developer and manager has officially broken ground on a 165,000 square foot expansion of Ionis Pharmaceuticals’ (“Ionis”) main life sciences campus. Located in the San Diego life sciences submarket of Carlsbad, Ionis’ existing campus features approximately 250,000 square feet of lab and office space. The expansion builds on Oxford and Ionis’ established partnership, with Oxford completing a purchase and long-term lease back of Ionis’ existing campus in October 2022.

Continue Reading

Render for 165,000 SF expansion of Ionis’ Carlsbad life sciences campus and HQ (CNW Group/Oxford Properties Group Inc.)

Today’s announcement bolsters Oxford’s already robust global life sciences portfolio and West Coast presence, featuring additional high-quality assets in the Bay Area and Seattle. Oxford entered the San Diego life sciences market in February 2022 via a US$464 million acquisition of a 13-building portfolio. Oxford’s San Diego life sciences portfolio currently comprises more than 900,000 square feet, which will increase to over 1.3 million square feet upon completion of its development pipeline in market.

“We are very pleased to build on our significant partnership with Ionis, as we each write another chapter in our remarkable growth journeys through the expansion of their main campus,” said Tycho Suter, Vice President, Investments at Oxford. “Oxford is a long-term investor, committed to creating both economic and social value through real estate. Supporting the growth of a highly aligned partner in Ionis, who are deeply embedded in the Carlsbad community, delivers on both fronts as we help provide the infrastructure necessary to develop the life-saving therapeutics of tomorrow.”
Founded in 1989, Ionis is a publicly traded biotech company and a leader in discovering and developing RNA-targeted therapeutics. Ionis currently has four marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. It has a long history of R&D successes and has delivered multiple breakthroughs leveraging its expanding technology platform. The campus expansion supports Ionis’ strategic goals of prioritizing its wholly owned pipeline and advancing its drug discovery technology.”The state-of-the-art facility being built by our partner Oxford Properties is more than a building, it’s a testament to Ionis’ enduring commitment to discovering, developing and delivering novel medicines to patients who are living with serious diseases,” said Elizabeth L. Hougen, Executive Vice President and Chief Financial Officer of Ionis. “In the same way that Ionis-discovered therapies like SPINRAZA®, the first-ever approved medicine to treat spinal muscular atrophy, and QALSODY™, the first treatment targeting a genetic form of ALS, changed the lives of people battling these devastating diseases, we expect the science done within the walls of this building to have a positive impact on the lives of people with unmet medical needs in the years to come.”Located at 2830 Whiptail Loop in Carlsbad and slated for completion by the end of 2025, Ionis’ campus expansion will deliver 165,000 square feet of purpose-built lab and complementary office space. Bringing Ionis’ overall campus to over 400,000 square feet of space across four buildings, the buildings feature chemistry labs, biology labs and R&D support systems, as well as modern office space. Part of the prominent San Diego North County life sciences cluster, in addition to Ionis, Carlsbad is home to leading firms such as Novartis, Thermo Fisher and Genentech.San Diego continues to define itself as a top three US life sciences market, and one of the most important life sciences markets globally. Its ecosystem is anchored by renowned research institutions and non-profits including San Diego State University, UC San Diego, Scripps Research and the Sandford Burnham Prebys Medical Discovery Institute. Benefitting from this clustering of firms, institutions and associated talent established over decades, San Diego’s life sciences market has grown by 40% over the last 15 years.Oxford has invested in life sciences since 2017. It has built substantial expertise in the sector while deploying capital through a variety of equity and credit investments as well as cultivating a significant development pipeline. Oxford’s life sciences business operates across the top 10 North American life sciences markets and in leading European markets through holdings in London, Cambridge and Paris.
About Oxford Properties Group
Oxford Properties Group (“Oxford”) is a leading global real estate investor, developer and manager. Established in 1960, Oxford and its portfolio companies manage approximately C$85 billion of assets across four continents on behalf of their investment partners. Oxford’s owned portfolio encompasses logistics, office, retail, multifamily residential, life sciences, credit and hotels in global gateway cities and high-growth hubs. A thematic investor with a committed source of capital, Oxford invests in properties, portfolios, development sites, debt, securities and real estate businesses across the risk-reward spectrum. Together with its portfolio companies, Oxford is one of the world’s most active developers with over 70 projects currently underway globally across all major asset classes. Oxford is owned by OMERS, the Canadian defined benefit pension plan for Ontario’s municipal employees.
About Ionis Pharmaceuticals, Inc.
For more than 30 years, Ionis has been a leader in RNA-targeted therapy, pioneering new markets and changing standards of care. Ionis currently has four marketed medicines and a promising late-stage pipeline highlighted by cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision to become the leader in genetic medicine, utilizing a multi-platform approach to discover, develop and deliver life-transforming therapies.To learn more about Ionis visit www.ionispharma.com and follow us on Twitter @ionispharma.SOURCE Oxford Properties Group Inc.

Telehealth Utilization Decreased in September 2023 Nationally and in Every US Census Region

In September 2023, Hypertension Became the Top-Ranked Asynchronous Telehealth Diagnosis Nationally, according to FAIR Health’s Monthly Telehealth Regional TrackerNEW YORK, Dec. 5, 2023 /PRNewswire/ — At the national level and in every US census region, telehealth utilization decreased in September 2023, according to FAIR Health’s Monthly Telehealth Regional Tracker. The decline followed an increase nationally and in every region in August. Nationally, the decrease in September was 9.3 percent (a decline from 5.4 percent of medical claim lines in August to 4.9 percent in September).1 The largest decrease, however, was in the Midwest, where utilization fell 15.0 percent. In the West telehealth utilization fell 14.7 percent, and in the Northeast the decrease was 8.2 percent. The South had the smallest decrease, 7.0 percent. The data include claims for the privately insured population and Medicare Advantage but exclude Medicare Fee-for-Service and Medicaid.

Continue Reading

Monthly Telehealth Regional Tracker, September 2023

Asynchronous TelehealthIn September, for the first time in 2023, hypertension ranked in first place among asynchronous telehealth diagnoses nationally.2 It had ranked in second place in the earlier months of the year. In September, hypertension increased in its share of asynchronous telehealth claim lines nationally and in every region. It ranked first that month in the Midwest, Northeast and West and second in the South.

In September, diabetes mellitus entered the national top five rankings of asynchronous telehealth diagnoses (at number five) for the first time in 2023.
Top Five Telehealth DiagnosesIn September 2023, COVID-19 entered the rankings of the top five telehealth diagnoses in the Midwest (at number four) and fell out of the rankings in the South and West. COVID-19 remained in second place in the Northeast, the same rank as in August. Nationally, COVID-19 fell from third to fourth place.In September, the percentage of telehealth claim lines for mental health conditions continued to decrease nationally and in every region, as it had in August. However, mental health conditions remained the number one telehealth diagnosis nationally and in every region, as it had since March 2020.Audio-Only Telehealth UsageIn September 2023, as in previous months, rural areas showed higher utilization of audio-only telehealth than urban areas in every region except the South, where the pattern was reversed. Audio-only telehealth utilization increased in both rural and urban areas in every region and nationally, except for urban areas of the South, which had a decrease of 14.4 percent, and urban areas nationally, which had a decrease of 4.1 percent.Telehealth Cost CornerFor September 2023, the Telehealth Cost Corner spotlighted the cost of CPT®3 90846, 50-minute family psychotherapy without patient. Nationally, the median charge amount for this service when rendered via telehealth was $181.19, and the median allowed amount was $111.82.4About the Monthly Telehealth Regional TrackerLaunched in May 2020 as a free service, the Monthly Telehealth Regional Tracker uses FAIR Health data to track how telehealth is evolving from month to month. An interactive map of the four US census regions allows the user to view an infographic on telehealth in a specific month in the nation as a whole or in individual regions. Each infographic shows month-to-month changes in volume of telehealth claim lines and audio-only telehealth usage (urban versus rural); the Telehealth Cost Corner, which presents a specific telehealth procedure code with its median charge amount and median allowed amount; and that month’s top five telehealth diagnoses and top five diagnoses via asynchronous telehealth.FAIR Health President Robin Gelburd stated: “We welcome sharing these varying windows into telehealth utilization as it continues to evolve. This is one of the many ways we pursue our healthcare transparency mission.”For the Monthly Telehealth Regional Tracker, click here.Follow us on Twitter @FAIRHealthAbout FAIR HealthFAIR Health is a national, independent nonprofit organization that qualifies as a public charity under section 501(c)(3) of the federal tax code. It is dedicated to bringing transparency to healthcare costs and health insurance information through data products, consumer resources and health systems research support. FAIR Health possesses the nation’s largest collection of private healthcare claims data, which includes over 44 billion claim records and is growing at a rate of over 2 billion claim records a year. FAIR Health licenses its privately billed data and data products—including benchmark modules, data visualizations, custom analytics and market indices—to commercial insurers and self-insurers, employers, providers, hospitals and healthcare systems, government agencies, researchers and others. Certified by the Centers for Medicare & Medicaid Services (CMS) as a national Qualified Entity, FAIR Health also receives data representing the experience of all individuals enrolled in traditional Medicare Parts A, B and D; FAIR Health includes among the private claims data in its database, data on Medicare Advantage enrollees. FAIR Health can produce insightful analytic reports and data products based on combined Medicare and commercial claims data for government, providers, payors and other authorized users. FAIR Health’s systems for processing and storing protected health information have earned HITRUST CSF certification and achieved AICPA SOC 2 Type 2 compliance by meeting the rigorous data security requirements of these standards. As a testament to the reliability and objectivity of FAIR Health data, the data have been incorporated in statutes and regulations around the country and designated as the official, neutral data source for a variety of state health programs, including workers’ compensation and personal injury protection (PIP) programs. FAIR Health data serve as an official reference point in support of certain state balance billing laws that protect consumers against bills for surprise out-of-network and emergency services. FAIR Health also uses its database to power a free consumer website available in English and Spanish, which enables consumers to estimate and plan for their healthcare expenditures and offers a rich educational platform on health insurance. An English/Spanish mobile app offers the same educational platform in a concise format and links to the cost estimation tools. The website has been honored by the White House Summit on Smart Disclosure, the Agency for Healthcare Research and Quality (AHRQ), URAC, the eHealthcare Leadership Awards, appPicker, Employee Benefit News and Kiplinger’s Personal Finance. For more information on FAIR Health, visit fairhealth.org.Contact:Rachel KentSenior Director of Communications and MarketingFAIR Health646-396-0795[email protected]1 A claim line is an individual service or procedure listed on an insurance claim.2 Asynchronous telehealth is telehealth in which data are stored and forwarded (e.g., blood pressure or other cardiac-related readings transmitted electronically; A1c levels transmitted electronically).3 CPT © 2023 American Medical Association (AMA). All rights reserved.4 A charge amount is the provider’s undiscounted fee, which a patient may have to pay when the patient is uninsured, or when the patient chooses to go to a provider who does not belong to the patient’s plan’s network. An allowed amount is the total negotiated, in-network fee paid to the provider under an insurance plan. It includes the amount that the health plan pays and the part the patient pays under the plan’s in-network cost-sharing provisions (e.g., copay or coinsurance if the patient has met the deductible).SOURCE FAIR Health

Merit Medical Announces Proposed Private Placement of $550 Million of Convertible Senior Notes

SOUTH JORDAN, Utah, Dec. 04, 2023 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (Nasdaq: MMSI) (“Merit”), a leading global manufacturer and marketer of healthcare technology, announced today that it intends to offer, subject to market conditions and other factors, $550.0 million aggregate principal amount of Convertible Senior Notes due 2029 (the […]

Silence Therapeutics Strengthens Executive Leadership Team with Key Appointments

LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or the “Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced Curtis Rambaran, MD, previously Silence’s Vice President, Head of Clinical Science, has been promoted to Chief Medical Officer, and Marie […]

Johnson & Johnson MedTech Acquires Laminar, Inc.

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson MedTech1 today announced the completion of the acquisition2 of Laminar, Inc., a privately-held medical device company focused on eliminating the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation (AFib). Johnson & Johnson MedTech acquired Laminar for an upfront payment of $400 million, subject to […]

Nanox Announces Third Quarter of 2023 Financial Results and Provides Business Update

Reports progress towards global supply chain development and commercial deployment Ended the third quarter of 2023 with cash, cash equivalents, restricted cash and marketable securities of $95.6 million Management to host conference call and webcast Tuesday, November 28, 2023 at 8:30 AM ET Management to host investor day on December […]

Route 92 Medical Raises Over $31 Million in Oversubscribed Series F Equity Financing to Accelerate its Commercialization into the Rapidly Growing Stroke Treatment Market

SAN MATEO, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced it has raised over $31 million in a Series F financing to accelerate the commercial adoption of a neurovascular intervention […]

BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Westport, CT, Nov. 13, 2023 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) a medical technology company committed to delivering unprecedented accuracy and precision to intracardiac signal visualization, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 6,996,922 […]

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

U.S. FDA granted Investigational Device Exemption (“IDE”) approval to initiate the BACKBEAT pivotal study evaluating AVIM therapy (BackBeat CNT) in hypertensive pacemaker patients BACKBEAT pivotal study on track to start enrollment before the end of 2023, with a mid-2025 target for completion of enrollment Expected operating cash runway sufficient into […]